Exosomes derived from human dermal fibroblasts ( HDFn‐Ex ) alleviate DNCB ‐induced atopic dermatitis (AD) via PPARα
Experimental Dermatology · 2024-01 · 33 (1)
DOI: 10.1111/exd.14970 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Dermatology, online erschienen am 17.11.2023. Verfasst von You Na Jang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Graduate School, Chung-Ang University, Seoul, South Korea. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Exosomes, Skin Diseases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Chung-Ang University Research Scholarship Grants, National Research Foundation of Korea.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a chronic inflammatory skin disease. Skin barrier dysfunction is the initial step in the development of AD. Recently, exosomes have been considered as potential cell‐free medicine for skin defects such as aging, psoriasis and wounds. The aim of this study was to investigate the effects of human dermal fibroblast‐neonatal‐derived exosome (HDFn‐Ex) on AD. HDFn‐Ex increased the expression of peroxisome proliferator activated receptor α (PPARα) and alleviated the 1‐chloro‐2,4‐dinitrobenzene (DNCB)‐mediated downregulation of filaggrin, involucrin, loricrin, hyaluronic acid synthase 1 (HAS1) and HAS2 in human keratinocyte HaCaT cells. However, these effects were inhibited by the PPARα antagonist GW6471. In the artificial skin model, HDFn‐Ex significantly inhibited DNCB‐induced epidermal hyperplasia and the decrease in filaggrin and HAS1 levels via a PPARα. In the DNCB‐induced AD‐like mouse model, HDFn‐Ex administration reduced epidermis thickening and mast cell infiltration into the dermis compared to DNCB treatment. Moreover, the decreases in PPARα, filaggrin and HAS1 expression, as well as the increases in IgE and IL4 levels induced by DNCB treatment were reversed by HDFn‐Ex. These effects were blocked by pre‐treatment with GW6471. Furthermore, HDFn‐Ex exhibited an anti‐inflammatory effect by inhibiting the DNCB‐induced increases in IκBα phosphorylation and TNF‐α expression. Collectively, HDFn‐Ex exhibited a protective effect on AD. Notably, these effects were regulated by PPARα. Based on our results, we suggest that HDFn‐Ex is a potential candidate for treating AD by recovering skin barrier dysfunction and exhibiting anti‐inflammatory activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Graduate School, Chung-Ang University, Seoul, South Korea.
- Department of Dermatology, Chung-Ang University College of Medicine, Seoul, South Korea.
- Department of Dermatology, Chung-Ang University Gwang-Myeong Hospital, Chung-Ang University College of Medicine, Seoul, South Korea.
ORCID-Profile: You Na Jang, Jung Ok Lee, Jung Min Lee, A Yeon Park, Yu Jin Kim, Su Young Kim, Joon Seok, Kwang Ho Yoo, Beom Joon Kim
Förderung
- Chung-Ang University Research Scholarship Grants
- National Research Foundation of Korea
Zitieren
APA
Jang, Y. N., Lee, J. O., Lee, J. M., Park, A. Y., Kim, Y. J., Kim, S. Y., Seok, J., Yoo, K. H., & Kim, B. J. (2024). Exosomes derived from human dermal fibroblasts ( HDFn‐Ex ) alleviate DNCB ‐induced atopic dermatitis (AD) via PPARα. Experimental Dermatology, 33(1). https://doi.org/10.1111/exd.14970
Vancouver
Jang YN, Lee JO, Lee JM, Park AY, Kim YJ, Kim SY, et al. Exosomes derived from human dermal fibroblasts ( HDFn‐Ex ) alleviate DNCB ‐induced atopic dermatitis (AD) via PPARα. Experimental Dermatology. 2024;33(1). doi:10.1111/exd.14970
BibTeX
@article{Jang2024,
author = {Jang, You Na and Lee, Jung Ok and Lee, Jung Min and Park, A Yeon and Kim, Yu Jin and Kim, Su Young and Seok, Joon and Yoo, Kwang Ho and Kim, Beom Joon},
title = {Exosomes derived from human dermal fibroblasts ( HDFn‐Ex ) alleviate DNCB ‐induced atopic dermatitis (AD) via PPARα},
journal = {Experimental Dermatology},
year = {2024},
volume = {33},
number = {1},
doi = {10.1111/exd.14970}
}
EUVIMED